Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis

作者：Cornet Edouard; Dumezy Florent; Roumier Christophe; Lepelley Pascale; Jouy Nathalie; Philippe Nathalie; Renneville Aline; Berthon Celine; Nelken Brigitte; Quesnel Bruno; Preudhomme Claude^*

来源：Leukemia Research, 2012, 36(11): 1330-1333.

DOI：10.1016/j.leukres.2012.07.001

• Acute myeloid leukaemia
• Core binding factor
• Systemic mastocytosis
• KIT mutation
• Minimal residual disease
• Leukaemic intiating cell

In core binding factor (CBF) acute myeloid leukaemia (AML), realtime quantitative PCR is useful to quantify the fusion transcript ratio (CBF beta-MYH11 and AML1-ETO, in case of inv(16) and t(8;21) respectively) in peripheral blood and bone marrow during the courses of chemotherapy, in order to monitor minimal residual disease (MRD). In two cases of CBF AML associated with systemic mastocytosis (SM), the persistence of mast cells and the detection of a high ratio of fusion transcript, in bone marrow, during the courses of chemotherapy, led us to determine whether the mast cell component of the disease carried the same molecular alterations as leukaemic blasts. We demonstrate that sorted mast cells carried CBF abnormality. These observations point out the lack of specificity of MRD monitoring by RQ-PCR in these exceptional AML cases with SM. Moreover, this suggests that leukaemic blasts and mast cells derive from a common malignant progenitor.

• 出版日期2012-11